

DEC 04 2007

PTO/SB/08a (05-97)

Approved for use through 11/30/2007, OMB 0551-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid CMB control number.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Not for submission under 37 CFR 1.99)

Application Number	10056680
Filing Date	2002-01-25
First Named Inventor	Teddy Kosoglou
Art Unit	1617
Examiner Name	San Ming R. Hui
Attorney Docket Number	CV 01492KUS (4686-045551)

U.S. PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S. PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20030119809		2003-08-26	Davis, Harry R.	
	2	20030119808		2003-08-26	Lebeaut, Alexandre P., et al.	
	3	20030119757		2003-08-26	Davis, Harry R.	
	4	20030053981		2003-03-20	Davis, Harry R. et al.	
	5	20020183305		2002-12-05	Davis, Harry R. et al.	

DEC-04-2007 17:10

The Webb Law Firm

DEC 04 2007 P.004

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10056680
Filing Date	2002-01-25
First Named Inventor	Teddy Kosoglou
Art Unit	1617
Examiner Name	San Ming R. Hui
Attorney Docket Number	CV 01492KUS (4686-045551)

6	20020169134	2002-11-14	Davis, Harry R.	
7	20030109442	2003-06-12	Bisgaier, Charles L., et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	TS
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	TS
	1	HAROLD BAYS, ET AL., "Pharmacotherapy for Dyslipidaemia - Current Therapies and Future Agents", Expert Opin. Pharmacother., Vol. 4, No. 11, pp. 1901-1938, (2003).	<input type="checkbox"/>
	2	CESARE R. SIRTORI, "New Targets For Lipid Lowering And Atherosclerosis Prevention", Pharmac. Ther. Vol. 67, No. 3, pp. 433-447, (1995).	<input type="checkbox"/>
	3	SANJAY KAUL, ET AL., "Intramural Delivery of Recombinant Apolipoprotein A-IMilano/Phospholipid Complex (ETC-216) Inhibits In-Stent Stenosis in Porcine Coronary Arteries", Circulation Vol. 107, pp. 2551-2554, (May 12, 2003).	<input type="checkbox"/>
	4	GIULIA CHIESA, ET AL., "Apolipoprotein A-IMilano: Current Perspectives", Curr. Opin. Lipidol, Vol. 14, pp. 159-163, (2003).	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Not for submission under 37 CFR 1.99)

Application Number	10056680
Filing Date	2002-01-25
First Named Inventor	Teddy Kosoglou
Art Unit	1617
Examiner Name	San Ming R. Hui
Attorney Docket Number	CV 01492KUS (4686-045551)

5	JOHN KASTELEIN, "What Future For Combination Therapies?", IJCP, pp. 45-50, (March 2003).	<input type="checkbox"/>
6	MARC EVANS, ET AL., "The Future Direction Of Cholesterol-Lowering Therapy", Curr. Opin. Lipidol, Vol. 13, pp. 663-669, (2002).	<input type="checkbox"/>
7	CRAIG W. SPELLMAN, "Management of Diabetes In the Real World: Tight Control Of Glucose Metabolism", JAOA, Supplement 5, Vol. 103, No. 8, (August, 2003).	<input type="checkbox"/>
8	ROBERT J. LIPSY, ET AL., "Optimizing Dyslipidemia Outcomes: A Novel Pharmacotherapeutic Pathway", JMCP, Vol. 9, No. 1, (January/February 2003).	<input type="checkbox"/>
9	PEDRO IGLESIAS, ET AL., "New Drugs For The Treatment Of Hypercholesterolaemia", Expert Opin. Investig. Drugs, Vol. 12, No. 11, pp. 1777-1789, (2003).	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Not for submission under 37 CFR 1.99)

Application Number	10056680
Filing Date	2002-01-25
First Named Inventor	Teddy Kosoglou
Art Unit	1617
Examiner Name	San Ming R. Hui
Attorney Docket Number	CV 01492KUS (4886-045551)

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

- ☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).


OR

- ☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- ☐ See attached certification statement.
- ☒ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☐ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature		Date (YYYY-MM-DD)	2007-12-04
Name/Print	Ann M. Cannon	Registration Number	35,972

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.